Today, our drug candidates are focused on treating rare, genetic metabolic diseases, with other major diseases on the horizon.

Synlogic is currently developing medicines that address disease from a base of operation in the gut microbiome or from within a tumor, using our proprietary approach to creating living Synthetic BioticTM medicines.

  • Our proprietary pipeline includes Synthetic Biotic medicines that are being evaluated in clinical trials for the treatment of phenylketonuria (PKU) and hyperammonemia, and an oncology program in IND-enabling studies.
  • In collaboration with partners, we will apply our proprietary platform to create innovative Synthetic Biotic medicines for the treatment of major diseases in disease areas including inflammation, metabolism, oncology and CNS.

Synlogic Pipeline November 2018